Target Name: DDAH2
NCBI ID: G23564
Review Report on DDAH2 Target / Biomarker Content of Review Report on DDAH2 Target / Biomarker
DDAH2
Other Name(s): dimethylargininase-2 | Protein G6a | DDAH2_HUMAN | dimethylarginine dimethylaminohydrolase 2 | dimethylarginine dimethylaminohydrolase II | N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 | Dimethylarginine dimethylaminohydrolase II | epididymis secretory protein Li 277 | DDAH2 variant 2 | Dimethylarginine dimethylaminohydrolase 2, transcript variant 2 | S-phase protein | testis tissue sperm-binding protein Li 54e | G6a | Dimethylargininase 2 | DDAH | HEL-S-277 | DDAHII | Dimethylarginine dimethylaminohydrolase 2 | NG30 | DDAH-2 | Dimethylargininase-2 | NG,NG-dimethylarginine dimethylaminohydrolase 2

Discovering and Characterizing DMA2: A Protein Involved in Several Diseases

Dimethylargininase-2 (DMA2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is a key enzyme in the cardiovascular system, involved in the regulation of blood-brain barrier (BBB) permeability and angiogenesis. DMA2 has also been shown to play a role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, DMA2 has emerged as a promising drug target for a variety of diseases.

The discovery and characterization of DMA2 came in the late 1990s, when researchers identified it as a gene that was highly expressed in the brain and was involved in the regulation of brain barrier function. Subsequent studies have shown that DMA2 is involved in several important processes in the brain, including the regulation of neurotransmitter release, cell signaling, and inflammation.

One of the key functions of DMA2 is its role in the regulation of the blood-brain barrier (BBB). The BBB is a specialized barrier that separates the brain from the blood and helps to protect it from harmful substances. However, this barrier is not always very selective, and some substances that are important for brain function can pass through the BBB and into the brain. DMA2 is involved in the regulation of BBB permeability, which is the ability of certain substances to come into or out of the brain.

DMA2 is also involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. Angiogenesis is a critical process for the development and maintenance of the blood supply, and is involved in the regulation of blood flow to the brain. DMA2 has been shown to play a role in the regulation of angiogenesis by promoting the formation of new blood vessels in the brain.

In addition to its role in the regulation of the BBB and angiogenesis, DMA2 has also been shown to be involved in the development and progression of several diseases. For example, DMA2 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that DMA2 levels are often elevated in the brains of people with these conditions, and that decreased DMA2 levels have been associated with the progression of these diseases.

DMA2 has also been shown to be involved in the development of autoimmune disorders, such as multiple sclerosis and rheumatoid arthritis. These conditions involve the immune system attacking the body's own tissues, and DMA2 has been shown to play a role in the regulation of the immune response.

In addition to its potential role in the development of these diseases, DMA2 has also been shown to have potential as a drug target. Researchers have identified several potential drug targets for DMA2, including those that are involved in the regulation of the BBB, angiogenesis, and the immune response. These targets are being targeted in order to develop new treatments for a variety of diseases.

One of the potential drug targets for DMA2 is the inhibition of its activity. Researchers have shown that DMA2 is involved in the regulation of a variety of cellular processes, including cell signaling, neurotransmitter release, and angiogenesis. As a result, drugs that inhibit DMA2 activity have the potential to treat a variety of diseases. For example, studies have shown that inhibiting DMA2 activity has the potential to treat neurodegenerative diseases, such as Alzheimer's disease, by reducing the formation of new blood vessels in the brain.

Another potential drug target for DMA2 is the stimulation of its activity. Researchers have shown that DMA2 is involved in the regulation of a variety of cellular processes, including cell signaling, neurotransmitter release, and angiogenesis. As a result, drugs that stimulate DMA2 activity have the potential to treat a variety of diseases. For example, studies have shown that

Protein Name: Dimethylarginine Dimethylaminohydrolase 2

Functions: Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation

The "DDAH2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDAH2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

DDB1 | DDB2 | DDC | DDC-AS1 | DDD core complex | DDHD1 | DDHD2 | DDI1 | DDI2 | DDIAS | DDIT3 | DDIT4 | DDIT4L | DDN | DDO | DDOST | DDR1 | DDR2 | DDRGK1 | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55 | DDX56 | DDX59 | DDX59-AS1 | DDX6 | DDX60 | DDX60L | DDX6P1 | DEAF1 | Death-associated protein kinase | Decapping Complex | DECR1 | DECR2 | DEDD | DEDD2 | Dedicator of cytokinesis protein | DEF6 | DEF8 | DEFA1 | DEFA10P | DEFA11P | DEFA1B | DEFA3 | DEFA4 | DEFA5 | DEFA6 | DEFA7P | DEFA8P | DEFA9P | DEFB1 | DEFB103A | DEFB103B | DEFB104A | DEFB104B | DEFB105A